Dynamic changes in systemic immune-inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy

Demircan N. C., Atci M. M., Demir M., Isik S., Akagunduz B.

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, vol.19, no.1, pp.104-112, 2023 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 1
  • Publication Date: 2023
  • Doi Number: 10.1111/ajco.13784
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
  • Page Numbers: pp.104-112
  • Eskisehir Osmangazi University Affiliated: Yes


Aim Systemic inflammation has been associated with chemoresistance and prognosis in solid tumors. Systemic immune-inflammation index (SII) is a novel marker derived from complete blood count. We investigated whether differences between SIIs measured before and after neoadjuvant chemotherapy (NACT) are associated with tumor regression grade (TRG) and survival in gastric and gastroesophageal junction (GEJ) cancer patients. Methods Records of gastric and GEJ cancer patients treated with NACT in two centers were evaluated retrospectively. Patients were categorized according to difference between pre- and post-NACT SII values (Delta SII). Association between clinicopathological factors and TRG was analyzed using logistic regression method. Predictors of disease-free and overall survival (DFS and OS) were determined with Cox regression models. Results The study included 140 patients. Patients with Delta SII<0 were more likely to achieve TRG 0/1 (45.2% vs. 19.1%, p = 0.003) and Delta SII<0 was an independent predictor of TRG 0/1 (OR = 6.05, p<0.001). DFS and OS of patients with Delta SII<0 were also significantly longer (p = 0.031 and p = 0.006, respectively). After adjustment for other variables, Delta SII >= 0 was an independent prognostic factor for OS (Hazard ratio (HR) = 2.13, p = 0.008). Conclusions Changes in SII, which is a low-cost and easily accessible marker, may be used to estimate prognosis, individualize postoperative treatment and optimize surveillance in gastric and GEJ cancer patients treated with NACT.